Is the one shot jab a game changer?
From our UK edition
The UK’s decision to lengthen the gap between first and second doses of the Pfizer and AstraZeneca vaccines has been criticised by some. But what if we had a vaccine which only needed one dose, and had been tested on that basis? A vaccination programme could progress far more quickly and without the complication of having to ask people to come back to a clinic a second time. In particular, it would simplify the distribution of vaccines in countries with less-well developed public health systems. That is the promise of the latest vaccine candidate for which results have been reported: the Johnson & Johnson vaccine, which is based on an existing Ebola jab.